1. The abrdn Healthcare Investors fund is rated 'sell' due to its mismatch with income investing and managed distribution plans; 2. The fund has underperformed the Nasdaq Biotechnology Index and iShares Biotechnology ETF, indicating its inability to generate alpha compared to more tax-efficient alternatives; 3. The fund's high yield is unsustainable, relying on capital gains and potentially forcing premature sales, which is not suitable for income-oriented investors.